IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA

IDEC-Y2B8(IDEC-103)是一种小鼠IgG1 kappa单抗。 C2B8(IDEC-102)是一种嵌合的IgG1 kappa单抗，与小鼠 可变区和人类恒定区。这两种抗体都能识别并显示 CD20抗原在正常B细胞和MOST细胞上表达的特异性 恶性B细胞淋巴瘤。食蟹猴大剂量安全性研究 都没有发现任何一种抗体的不良临床事件，而且 实验室检查或组织病理学检查均未见明显异常。

IDEC-Y2B8 (IDEC-103) is a murine IgG1 kappa monoclonal antibody and IDEC- C2B8 (IDEC-102) is a chimeric igG1 kappa monoclonal antibody, with mouse variable and human constant regions. Both antibodies recognize and show specificity for the CD20 antigen expressed on normal B cells and most malignant B-cell lymphomas. High-dose safety studies in cynomolgus monkeys have revealed no adverse clinical events with either antibody, and there were no significant abnormalities on laboratory tests or on histopathology.